UNITED THERAPEUTICS Corp - Common Stock (UTHR)

Historical Holders from Q1 2014 to Q3 2025

Symbol
UTHR on Nasdaq
Type / Class
Equity / Common Stock
Shares outstanding
44.8M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
40.9M
Holdings value
$17.1B
% of all portfolios
0.022%
Grand Portfolio weight change
-0.002%
Number of holders
692
Number of buys
310
Number of sells
-347
Average Value change %
+0%
Average buys %
+0.007%
Average sells %
-0.005%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of UNITED THERAPEUTICS Corp - Common Stock (UTHR)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
STATE STREET CORP 4.9% $662M 2.2M STATE STREET CORPORATION 31 Dec 2024
WELLINGTON MANAGEMENT GROUP LLP 4.5% -16.7% $609M -$132M 2.03M -17.8% Wellington Management Group LLP 31 Mar 2025

Institutional Holders of UNITED THERAPEUTICS Corp - Common Stock (UTHR)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 40.9M $17.1B -$1.07B $419.21 692
2025 Q2 43.9M $12.6B -$132M $287.35 662
2025 Q1 44.4M $13.7B +$58.4M $308.27 661
2024 Q4 44M $15.5B +$61M $352.84 667
2024 Q3 43.5M $15.6B -$720M $358.35 617
2024 Q2 45.8M $14.6B +$331M $318.55 557
2024 Q1 45.1M $10.4B +$141M $229.72 518
2023 Q4 44.5M $9.79B +$24.5M $219.89 528
2023 Q3 44.4M $10B -$138M $225.87 503
2023 Q2 44.9M $9.92B -$54M $220.75 466
2023 Q1 45.1M $10.1B -$14.2M $223.96 499
2022 Q4 44.9M $12.5B +$52.1M $278.09 506
2022 Q3 44.8M $9.37B +$62.5M $209.38 450
2022 Q2 44M $10.4B +$127M $235.64 462
2022 Q1 44M $7.89B +$134M $179.41 416
2021 Q4 43.1M $9.32B -$262M $216.08 409
2021 Q3 44.1M $8.15B +$112M $184.58 415
2021 Q2 43.5M $7.79B +$9.01M $179.41 397
2021 Q1 43.4M $7.27B +$26.8M $167.27 384
2020 Q4 43M $6.53B +$196M $151.79 347
2020 Q3 41.9M $4.23B -$29.1M $101.00 320
2020 Q2 42.1M $5.09B -$63.2M $121.00 338
2020 Q1 42.9M $4.07B +$175M $94.83 293
2019 Q4 41.2M $3.63B -$10.8M $88.08 313
2019 Q3 41.4M $3.3B -$43.2M $79.75 293
2019 Q2 41.9M $3.27B -$121M $78.06 310
2019 Q1 42.9M $5.02B -$2.5M $117.37 365
2018 Q4 42.8M $4.65B -$44.4M $108.90 349
2018 Q3 42.9M $5.48B +$109M $127.88 358
2018 Q2 42.2M $4.76B -$157M $113.15 363
2018 Q1 43.5M $4.87B -$69.3K $112.36 365
2017 Q4 43.8M $6.47B +$1.7M $147.95 396
2017 Q3 43.7M $5.13B -$335M $117.19 366
2017 Q2 46.3M $6.01B -$200M $129.73 370
2017 Q1 47.8M $6.47B +$611M $135.38 403
2016 Q4 47.5M $6.8B -$130M $143.43 399
2016 Q3 48.6M $5.74B -$95.8M $118.08 386
2016 Q2 49.5M $5.24B -$126M $105.92 376
2016 Q1 50.9M $5.67B -$72.5M $111.43 392
2015 Q4 51M $7.99B +$6.72M $156.61 379
2015 Q3 50.9M $6.68B -$88.6M $131.24 364
2015 Q2 51M $8.87B -$239M $173.95 382
2015 Q1 52.4M $9.03B +$259M $172.43 364
2014 Q4 51M $6.61B -$258M $129.49 329
2014 Q3 52.8M $6.8B +$111M $128.65 316
2014 Q2 52.2M $4.62B -$148M $88.49 302
2014 Q1 53.8M $5.06B -$116M $94.03 305